Details of Disease

General Information of Disease (ID: DISYNSM9)

• Disease Name: Hypotension
• Synonyms: hypotension (disease); hypotension
• Disease Class: BA20-BA21: Hypotension
• Definition: Blood pressure that is abnormally low.
• Disease Hierarchy:
  DISLG4XS: Arterial disorder
  DISYNSM9: Hypotension
• ICD Code:
  ICD-11: ICD-11: BA20-BA21
  Expand ICD-11: 'BA2Z
  Expand ICD-10: 'I95; 'I95.2; 'I95.8; 'I95.9
  Expand ICD-9: 458796.3
• Disease Identifiers:
  MONDO ID: MONDO_0005468
  MESH ID: D007022
  UMLS CUI: C0020649
  MedGen ID: 5715
  HPO ID: HP:0002615
  SNOMED CT ID: 45007003

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 5 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Amezinium	DM6I2WQ	Approved	Small molecular drug	[1]
Dopamine	DMPGUCF	Approved	Small molecular drug	[2]
Hemoglobin crosfumaril	DM4V3WO	Approved	NA	[1]
Metaraminol	DMWIX23	Approved	Small molecular drug	[3]
Pentolinium	DM38VYQ	Approved	Small molecular drug	[4]

This Disease is Treated as An Indication in 7 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Darusentan	DMN8DQH	Phase 3	Small molecular drug	[5]
Alagebrium chloride	DMD741P	Phase 2/3	Small molecular drug	[6]
MTR105	DMT0K4F	Phase 2	Small molecular drug	[7]
NOX-100	DMBIM92	Phase 2	NA	[8]
Sampatrilat	DMXTOVE	Phase 2	Small molecular drug	[9]
TBC-3711	DMZCA0K	Phase 2	Small molecular drug	[10]
GW-796406	DMQ46DN	Phase 1	NA	[11]

This Disease is Treated as An Indication in 10 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Hemoximer	DMGYKDN	Discontinued in Phase 3	NA	[12]
Fasidotril	DMRU1KT	Discontinued in Phase 2	Small molecular drug	[13]
Gemopatrilat	DMLMT5O	Discontinued in Phase 2	Small molecular drug	[14]
M-100240	DMQ1LWU	Discontinued in Phase 2	Small molecular drug	[15]
METIAPRIL	DM90SHY	Discontinued in Phase 2	NA	[16]
SCH-42495	DM2RH51	Discontinued in Phase 2	Small molecular drug	[17]
SGB-1534	DMBG6LP	Discontinued in Phase 2	Small molecular drug	[18]
Zolasartan	DM9FQI0	Discontinued in Phase 2	Small molecular drug	[19]
ZD-1611	DMUDLFM	Discontinued in Phase 1	NA	[20]
Patamostat	DM6HBQJ	Terminated	Small molecular drug	[21]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 49 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ADK	TTL732K	Limited	Biomarker	[22]
ADRA1A	TTNGILX	Limited	Biomarker	[23]
CRHR2	TTIY658	Limited	Biomarker	[24]
NPPB	TTY63XT	Limited	Biomarker	[25]
POR	TTOQ9GZ	Limited	Biomarker	[26]
PTAFR	TTQL5VC	Limited	Therapeutic	[27]
PTGER4	TT79WV3	Limited	Biomarker	[28]
S100B	TTQ0V86	Limited	Biomarker	[29]
TACR1	TTZPO1L	Limited	Biomarker	[30]
TACR3	TTBPGLU	Limited	Biomarker	[31]
XDH	TT7RJY8	Limited	Biomarker	[32]
CNR1	TT6OEDT	Disputed	Biomarker	[33]
AVP	TTJ8EWH	moderate	Biomarker	[34]
ADORA1	TTK25J1	Strong	Biomarker	[35]
ADORA2A	TTM2AOE	Strong	Biomarker	[35]
ADRA1B	TTBRKXS	Strong	Biomarker	[36]
ADRA2A	TTWG9A4	Strong	Biomarker	[37]
AGT	TT5C0UB	Strong	Therapeutic	[38]
ALB	TTFNGC9	Strong	Biomarker	[39]
BDKRB2	TTGY8IW	Strong	Biomarker	[40]
CAT	TTPS279	Strong	Therapeutic	[41]
CRH	TTA7YIZ	Strong	Biomarker	[42]
CTF1	TTXGTZU	Strong	Biomarker	[43]
DRD1	TTZFYLI	Strong	Biomarker	[44]
DRD2	TTEX248	Strong	Biomarker	[44]
EDN1	TTJR60Z	Strong	Altered Expression	[45]
EDN2	TTMR0OP	Strong	Therapeutic	[46]
FGF1	TTMY81X	Strong	Biomarker	[47]
GCG	TT6Y4PN	Strong	Therapeutic	[48]
GRIA1	TTVPQTF	Strong	Biomarker	[49]
GRIN2B	TTN9D8E	Strong	Biomarker	[49]
HRH1	TTTIBOJ	Strong	Biomarker	[50]
HTR1B	TTK8CXU	Strong	Biomarker	[51]
HTR1D	TT6MSOK	Strong	Biomarker	[51]
IL1A	TTPM6HI	Strong	Biomarker	[52]
IL2	TTF89GD	Strong	Biomarker	[53]
INS	TTZOPHG	Strong	Biomarker	[54]
KNG1	TTDJ4MY	Strong	Biomarker	[55]
LTF	TTSZDQU	Strong	Biomarker	[56]
MAOA	TT3WG5C	Strong	Biomarker	[57]
MAOB	TTGP7BY	Strong	Biomarker	[57]
NISCH	TT789FN	Strong	Biomarker	[58]
PLAT	TTXAGYU	Strong	Biomarker	[59]
PLAU	TTGY7WI	Strong	Biomarker	[60]
PRL	TTJ2TSA	Strong	Biomarker	[61]
REN	TTB2MXP	Strong	Therapeutic	[62]
SLC9A3	TTFZVPO	Strong	Biomarker	[63]
SOD1	TTP9K3Q	Strong	Biomarker	[64]
VIP	TTGTWLF	Strong	Biomarker	[65]

This Disease Is Related to 2 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
GSTM1	DEYZEJA	Limited	Biomarker	[26]
SULT1A1	DEYWLRK	Limited	Biomarker	[26]

This Disease Is Related to 9 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
PLCD1	OT6WFVXZ	Limited	SusceptibilityMutation	[66]
TAC1	OTM842YW	Disputed	Biomarker	[67]
ACE	OTDF1964	Strong	Therapeutic	[68]
EDN3	OTN7Q9BE	Strong	Therapeutic	[69]
NPPA	OTMQNTNX	Strong	Biomarker	[70]
OXT	OT48M72Z	Strong	Biomarker	[62]
PDYN	OTEJ6430	Strong	Biomarker	[71]
PNOC	OTJEAADN	Strong	Biomarker	[72]
SCNN1G	OTSJYQVQ	Strong	Biomarker	[73]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 940).
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7229).
• [4] Drug information of Pentolinium, 2008. eduDrugs.
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3508).
• [6] ClinicalTrials.gov (NCT01417663) Effects of Exercise Training and AGE-crosslink Breaker on Cardiovascular Structure and Function. U.S. National Institutes of Health.
• [7] ClinicalTrials.gov (NCT00482287) Pharmacokinetics and Pharmacodynamics of MTR105 in Hypotensive Cardiac Surgery Patients. U.S. National Institutes of Health.
• [8] ClinicalTrials.gov (NCT01672008) NOX-100 for Preventing Hypotension During Hemodialysis. U.S. National Institutes of Health.
• [9] Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects. Am J Hypertens. 1999 Jun;12(6):563-71.
• [10] ClinicalTrials.gov (NCT00272961) A Study Of Different Doses Of TBC3711 In Patients With Uncontrolled High Blood Pressure Already Taking Medications For High Blood Pressure.. U.S. National Institutes of Health.
• [11] Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-... J Pharmacol Exp Ther. 2005 Dec;315(3):1306-13.
• [12] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008774)
• [13] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6501).
• [14] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009581)
• [15] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002832)
• [16] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005081)
• [17] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002070)
• [18] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000148)
• [19] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001788)
• [20] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008908)
• [21] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003114)
• [22] Adenosine kinase inhibitor GP515 attenuates hepatic leukocyte adhesion after hemorrhagic hypotension.Am J Physiol. 1997 Dec;273(6):G1297-303. doi: 10.1152/ajpgi.1997.273.6.G1297.
• [23] Evidence that NAN-190-induced hypotension involves vascular alpha1-adrenoceptor antagonism in the rat.Eur J Pharmacol. 2002 Nov 22;455(1):59-64. doi: 10.1016/s0014-2999(02)02579-7.
• [24] Antalarmin blockade of corticotropin releasing hormone-induced hypertension in rats.Brain Res. 2000 Oct 27;881(2):204-7. doi: 10.1016/s0006-8993(00)02742-6.
• [25] Low-dose nesiritide improves renal function in heart failure patients following acute myocardial infarction.Heart Vessels. 2010 Mar;25(2):97-103. doi: 10.1007/s00380-009-1171-0. Epub 2010 Mar 26.
• [26] A physiogenomic approach to study the regulation of blood pressure.Physiol Genomics. 2005 Sep 21;23(1):46-53. doi: 10.1152/physiolgenomics.00077.2005. Epub 2005 Jun 7.
• [27] Platelet-activating factor (PAF) mediation of rat anaphylactic responses to soluble immune complexes. Studies with PAF receptor antagonist L-652,731.J Immunol. 1986 Jun 15;136(12):4659-68.
• [28] A prostaglandin E2 receptor subtype EP4 agonist attenuates cardiovascular depression in endotoxin shock by inhibiting inflammatory cytokines and nitric oxide production.Shock. 2004 Jul;22(1):76-81. doi: 10.1097/01.shk.0000129338.99410.5d.
• [29] Brain damage following severe acute normovolemic hemodilution in combination with controlled hypotension in rats.Acta Anaesthesiol Scand. 2007 Nov;51(10):1331-7. doi: 10.1111/j.1399-6576.2007.01448.x.
• [30] Exercise reduces GABA synaptic input onto nucleus tractus solitarii baroreceptor second-order neurons via NK1 receptor internalization in spontaneously hypertensive rats.J Neurosci. 2009 Mar 4;29(9):2754-61. doi: 10.1523/JNEUROSCI.4413-08.2009.
• [31] Blockade of NK3R signaling in the PVN decreases vasopressin and oxytocin release and c-Fos expression in the magnocellular neurons in response to hypotension.Am J Physiol Regul Integr Comp Physiol. 2008 Oct;295(4):R1158-67. doi: 10.1152/ajpregu.90402.2008. Epub 2008 Jul 23.
• [32] The role of xanthine oxidase in platelet activating factor induced intestinal injury in the rat.Gut. 1999 Feb;44(2):203-11. doi: 10.1136/gut.44.2.203.
• [33] Central cannabinoid 1 receptor antagonist administration prevents endotoxic hypotension affecting norepinephrine release in the preoptic anterior hypothalamic area.Shock. 2009 Dec;32(6):614-20. doi: 10.1097/SHK.0b013e3181a4fd8f.
• [34] Serum vasopressin response in patients with intradialytic hypotension: a pilot study.Clin J Am Soc Nephrol. 2008 May;3(3):729-35. doi: 10.2215/CJN.05341107. Epub 2008 Feb 6.
• [35] Hypotensive effects of intravenously administered uridine and cytidine in conscious rats: involvement of adenosine receptors.Eur J Pharmacol. 2008 Apr 14;584(1):125-36. doi: 10.1016/j.ejphar.2008.01.044. Epub 2008 Feb 9.
• [36] Hypotension, autonomic failure, and cardiac hypertrophy in transgenic mice overexpressing the alpha 1B-adrenergic receptor.J Biol Chem. 2001 Apr 27;276(17):13738-43. doi: 10.1074/jbc.M008693200. Epub 2001 Feb 1.
• [37] Brainstem adenosine A1 receptor signaling masks phosphorylated extracellular signal-regulated kinase 1/2-dependent hypotensive action of clonidine in conscious normotensive rats.J Pharmacol Exp Ther. 2009 Jan;328(1):83-9. doi: 10.1124/jpet.108.143883. Epub 2008 Oct 10.
• [38] Nitric oxide and the renin angiotensin system: contributions to blood pressure in the young rat.Pediatr Nephrol. 1997 Oct;11(5):617-22. doi: 10.1007/s004670050349.
• [39] [A case report. Hypotensive reaction caused by albumin infusion].Lakartidningen. 2001 Jan 31;98(5):439-42.
• [40] A pilot study indicating that bradykinin B2 receptor antagonism attenuates protamine-related hypotension after cardiopulmonary bypass.Clin Pharmacol Ther. 2005 Nov;78(5):477-85. doi: 10.1016/j.clpt.2005.08.010.
• [41] Effects of various antioxidants on endotoxin-induced lung injury and gene expression: mRNA expressions of MnSOD, interleukin-1beta and iNOS.Chin J Physiol. 2004 Sep 30;47(3):111-20.
• [42] Attenuation of corticotropin releasing factor-induced hypotension in anesthetized rats with the CRF antagonist, alpha-helical CRF9-41; comparison with effect on ACTH release.Peptides. 1992 Jan-Feb;13(1):1-6. doi: 10.1016/0196-9781(92)90132-m.
• [43] Induction of JAB/SOCS-1/SSI-1 and CIS3/SOCS-3/SSI-3 is involved in gp130 resistance in cardiovascular system in rat treated with cardiotrophin-1 in vivo.Circ Res. 2001 Apr 13;88(7):727-32. doi: 10.1161/hh0701.088512.
• [44] Enhanced hypotensive response to intravenous apomorphine in chronic spinalized, conscious rats: role of spinal dopamine D(1) and D(2) receptors.Neurosci Lett. 2003 Oct 2;349(2):115-9. doi: 10.1016/s0304-3940(03)00793-6.
• [45] Is there a role for endothelin-1 in the hemodynamic changes during hemodialysis?.Clin Exp Nephrol. 2008 Oct;12(5):370-375. doi: 10.1007/s10157-008-0065-2. Epub 2008 Jun 21.
• [46] Evidence for antagonistic activity of endothelin for clonidine induced hypotension and bradycardia.Life Sci. 1992;50(2):153-60. doi: 10.1016/0024-3205(92)90297-3.
• [47] Kinins are implicated of the hypotensive effect of acidic fibroblast growth factor.Eur J Med Res. 1997 Jul 28;2(7):302-4.
• [48] Amelioration of nifedipine poisoning associated with glucagon therapy.Ann Emerg Med. 1993 Jul;22(7):1234-7. doi: 10.1016/s0196-0644(05)80998-9.
• [49] Signaling pathway of glutamate in the vestibular nuclei following acute hypotension in rats.Brain Res. 2008 Sep 10;1229:111-7. doi: 10.1016/j.brainres.2008.06.088. Epub 2008 Jul 2.
• [50] Contribution of prostacyclin to D-tubocurarine-induced hypotension in humans.Anesthesiology. 1990 Jan;72(1):28-32. doi: 10.1097/00000542-199001000-00006.
• [51] Interactions of GR127935, a 5-HT(1B/D) receptor ligand, with functional 5-HT receptors.Naunyn Schmiedebergs Arch Pharmacol. 1997 Apr;355(4):423-30. doi: 10.1007/pl00004964.
• [52] The role of circulating immune complexes and biocompatibility of staphylococcal protein A immunoadsorption in mitomycin C-induced hemolytic uremic syndrome.Am J Kidney Dis. 2004 Oct;44(4):e50-8.
• [53] Consolidation biochemotherapy for patients with advanced nonsmall cell lung carcinoma responding to induction PVM (cisplatin, vinblastine, mitomycin-C) regimen. A phase II study.Cancer. 1996 Jun 1;77(11):2251-7. doi: 10.1002/(SICI)1097-0142(19960601)77:11<2251::AID-CNCR11>3.0.CO;2-W.
• [54] Effect of hypotension and hyperosmolality on vasopressin and ACTH responses to hypoglycemia in conscious dogs.Am J Physiol. 1992 Aug;263(2 Pt 2):R382-8. doi: 10.1152/ajpregu.1992.263.2.R382.
• [55] Hypotensive mechanism of the extracts and artemetin isolated from Achillea millefolium L. (Asteraceae) in rats.Phytomedicine. 2011 Jul 15;18(10):819-25. doi: 10.1016/j.phymed.2011.02.005. Epub 2011 Mar 21.
• [56] Bovine lactoferrin has a nitric oxide-dependent hypotensive effect in rats.Am J Physiol Regul Integr Comp Physiol. 2004 Feb;286(2):R359-65. doi: 10.1152/ajpregu.00214.2003. Epub 2003 Oct 16.
• [57] Increased baroreceptor response in mice deficient in monoamine oxidase A and B.Am J Physiol Heart Circ Physiol. 2002 Mar;282(3):H964-72. doi: 10.1152/ajpheart.00309.2001.
• [58] Adenosinergic modulation of the imidazoline I?receptor-dependent hypotensive effect of ethanol in acute renal failure.Food Chem Toxicol. 2012 Aug;50(8):2622-8. doi: 10.1016/j.fct.2012.05.015. Epub 2012 May 18.
• [59] Evaluation and comparison of the adverse effects of streptokinase and alteplase.Pharmacotherapy. 1992;12(6):440-4.
• [60] Low- versus high-dose recombinant urokinase for the treatment of chronic saphenous vein graft occlusion.Am J Cardiol. 1999 Jun 15;83(12):1623-8. doi: 10.1016/s0002-9149(99)00163-0.
• [61] Effects of anterior pituitary hormones and their releasing hormones on physiological and behavioral functions in rats.J Steroid Biochem. 1983 Jul;19(1B):433-8. doi: 10.1016/0022-4731(83)90200-5.
• [62] Oxytocin antagonist disrupts hypotension-evoked renin secretion and other responses in conscious rats.Am J Physiol Regul Integr Comp Physiol. 2001 Mar;280(3):R760-5. doi: 10.1152/ajpregu.2001.280.3.R760.
• [63] Role of the Na+/H+ exchanger 3 in angiotensin II-induced hypertension in NHE3-deficient mice with transgenic rescue of NHE3 in small intestines.Physiol Rep. 2015 Nov;3(11):e12605. doi: 10.14814/phy2.12605.
• [64] Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension.Circulation. 1997 Feb 4;95(3):588-93. doi: 10.1161/01.cir.95.3.588.
• [65] Glibenclamide-sensitive hypotension produced by helodermin assessed in the rat.Biol Pharm Bull. 1998 Dec;21(12):1290-3. doi: 10.1248/bpb.21.1290.
• [66] Hypotensive effect associated with a phospholipase C-delta 1 gene mutation in the spontaneously hypertensive rat.Biochem Biophys Res Commun. 1992 Sep 30;187(3):1359-66. doi: 10.1016/0006-291x(92)90452-q.
• [67] Warm SPA-induced hyperthermia confers protection to rats against airway inflammation evoked by capsaicin and substance P.Auton Neurosci. 2010 Jun 24;155(1-2):49-58. doi: 10.1016/j.autneu.2010.01.006.
• [68] Abnormal blood pressure recovery during ganglion blockade in diabetic rats.Am J Physiol. 1987 Jan;252(1 Pt 2):R102-8. doi: 10.1152/ajpregu.1987.252.1.R102.
• [69] Central sympathetic control of spinal endothelin release in the rat.Eur J Pharmacol. 1994 Jul 11;259(3):305-8. doi: 10.1016/0014-2999(94)90658-0.
• [70] alpha-ANP alters reflex control of lumbar and renal sympathetic nerve activity and heart rate.Am J Physiol. 1987 Nov;253(5 Pt 2):H1136-40. doi: 10.1152/ajpheart.1987.253.5.H1136.
• [71] Effects of dynorphin A(1-13) and of fragments of beta-endorphin on blood pressure and heart rate of anesthetized rats.Can J Physiol Pharmacol. 1991 Mar;69(3):327-33. doi: 10.1139/y91-050.
• [72] Nociceptin receptor activation produces nitric oxide-mediated systemic hypotension.Life Sci. 2000;66(6):PL99-104. doi: 10.1016/s0024-3205(99)00627-x.
• [73] Association of sodium channel gamma-subunit promoter variant with blood pressure.Hypertension. 2001 Jul;38(1):86-9. doi: 10.1161/01.hyp.38.1.86.